Ensartinib: clinical trials recruiting now
4
Recruiting trials
7
Conditions studied
0
US states with sites
1
Countries
FDA drug label
- FDA-approved
- Yes. Ensartinib appears in the FDA drug-label database. Marketed as ENSACOVE.
FDA-approved use
ENSACOVE is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)as detected by an FDA-approved test [see Dosage and Administration ( 2.1 )] who have not previously received an ALK-inhibitor. ENSACOVE is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test who have not previously received an ALK-inhibitor. ( 1 , 2.1 )
Phase breakdown
Phase 2 2
Phase 3 1
Not applicable 1
Conditions being studied
| Condition | Trials |
|---|---|
| Lung cancer · Ensartinib for Lung cancer | 4 |
| Non-small Cell Lung Cancer | 2 |
| Anaplastic Lymphoma Kinase I1171N | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Ensartinib | 1 |
| Lung Cancer Stage III | 1 |
| Mutation | 1 |
Recruiting trials involving Ensartinib
- A Real World Study of Ensartinib in Advanced ALK-positive NSCLC
- Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer
- Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer
- Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
Common questions
Is Ensartinib FDA-approved?
Yes, marketed as ENSACOVE.
How many recruiting trials involve Ensartinib?
4 recruiting trials across 7 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.